Ginkgo Datapoints partners with Lilly TuneLab on AI-driven drug discovery lab data generation

By Public Technologies
  • Ginkgo Bioworks struck an agreement with Lilly’s TuneLab platform to provide lab data generation services for AI-driven drug discovery.
  • Ginkgo Datapoints will run small-molecule ADME testing plus antibody developability screening for TuneLab participants.
  • Standardized assays aim to feed ML-ready datasets into TuneLab models, tightening the design-to-lab validation cycle.
  • TuneLab companies can submit Datapoints-generated results to access additional platform model benefits.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ginkgo Bioworks Holdings Inc. published the original content used to generate this news brief on September 16, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.